2023-509935-23-00
Completed
Phase 2
A Phase 2, Two-Part, Multiple-Ascending-Dose Study of SRP-5051 for Dose Determination, then Dose Expansion, in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
Sarepta Therapeutics Inc.8 sites in 5 countries21 target enrollmentStarted: May 6, 2024Last updated:
Overview
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Sarepta Therapeutics Inc.
- Enrollment
- 21
- Locations
- 8
- Primary Endpoint
- Part A: Incidence of Adverse Events (AEs), Baseline up to 75 weeks
Overview
Brief Summary
Part A: To evaluate the safety and tolerability of multiple ascending doses of SRP-5051, administered intravenously (IV) every 4 weeks, and determine the maximum tolerated dose (MTD) Part B: To evaluate dystrophin protein level in skeletal muscle tissue following SRP-5051 treatment, administered IV every 4 weeks at the doses selected based on data from Part A
Study Design
- Allocation
- Not Applicable
- Primary Purpose
- Part B Screening; Safety Lead-in Period; Treatment and Observation Period; Study Safety FU Period
- Masking
- None
Eligibility Criteria
- Ages
- 0 years to 64 years (0-17 Years, 18-64 Years)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Inclusion Criteria for participants previously treated with Vesleteplirsen: - Has received prior Vesleteplirsen treatment in Part A of this study or in Study 5051-
- •Inclusion Criteria for treatment-naïve participants enrolling into Part B: - Has a genetic diagnosis of Duchenne muscular dystrophy (DMD) and an out-of-frame deletion mutation of the DMD gene amenable to exon 51-skipping treatment. - Has been on a stable dose of oral corticosteroids for at least 12 weeks prior to study drug administration and the dose is expected to remain constant throughout the study (except for modifications to accommodate changes in weight), or has not received corticosteroids for at least 12 weeks prior to study drug administration. - Has stable pulmonary function (forced vital capacity [FVC] ≥40% of predicted and no requirement for nocturnal ventilation).
Exclusion Criteria
- •Exclusion Criteria for participants previously treated with Vesleteplirsen and new participants enrolling into Part B: - Presence of other clinically significant illness, including cardiac, pulmonary, hepatic, renal, hematologic, immunologic, or behavioral disease, or infection or malignancy or any other condition that, in the Investigator's opinion, could interfere with participation in the trial.
- •Exclusion Criteria for treatment-naive participants enrolling into Part B: - History of hypomagnesemia within 12 weeks prior to Screening. - Initiation or change of dosing (except for modifications to accommodate changes in weight or changes in standard of care) within 12 weeks prior to Screening for any of the following: angiotensin-converting enzyme inhibitors, angiotensin receptor-blocking agents, β-blockers, or potassium. - Initiation or change of dosing within 12 weeks prior to Screening for over-the-counter preparations, such as herbal/nonherbal supplements, vitamins, minerals, and homeopathic preparations. - Has a left ventricular ejection fraction (LVEF) <40.0% based on an echocardiogram (ECHO) performed within 12 weeks prior to Screening or at the Screening Visit. - Treatment with any exon 51-skipping therapy within 4 weeks prior to Screening, or with any experimental gene therapy for the treatment of DMD at any time. - Other inclusion/exclusion criteria apply.
Outcomes
Primary Outcomes
Part A: Incidence of Adverse Events (AEs), Baseline up to 75 weeks
Part A: Incidence of Adverse Events (AEs), Baseline up to 75 weeks
Part B: Change From Baseline in Dystrophin Protein Level at Week 28
Part B: Change From Baseline in Dystrophin Protein Level at Week 28
Secondary Outcomes
- Part A: Pharmacokinetics (PK): Plasma Concentration of Vesleteplirsen, Pre-dose and at multiple time points (up to 32 hours) after end of infusion
- Part A: PK: Urine Concentration of Vesleteplirsen, Pre-dose and at multiple time periods (up to 48 hours) after end of infusion
- Part B: Change From Baseline in Exon-Skipping Levels at Week 28
- Part B: Incidence of Adverse Events (AEs), Baseline up to Week 304
- Part B: PK: Plasma Concentration of Vesleteplirsen, Part B predose and at multiple timepoints (up to 48 hours) after end of infusion
- Part B: PK: Urine Concentration of Vesleteplirsen, Part B predose and at multiple timepoints (up to 48 hours) after end of infusion
- Part B: Change from Baseline in Percent Dystrophin-Positive Fibers (PDPF) and Mean Intensity, as Measured by Immunofluorescence Assay at Week 28
Investigators
Patient Recruitment
Scientific
Sarepta Therapeutics Inc.
Study Sites (8)
Loading locations...
Similar Trials
Recruiting
Not Applicable
TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant TumorsNCT07266298Neowise Biotechnology24
Recruiting
Phase 1
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor PatientsNCT07260305Kangabio AUSTRALIA LTD PTY57
Recruiting
Phase 1
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)NCT07260812TCRx Therapeutics Co.Ltd18
Completed
Phase 2/3
A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and subjects with thyroid eye disease (TED)2024-512244-36-00Viridian Therapeutics Inc.48
Not yet recruiting
Not Applicable
QTc Assessment in a Single-Dose Study of Hydronidone CapsulesNCT07263152Beijing Continent Pharmaceutical Co, Ltd.48